[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-465557-105":59,"doc-detail-465557-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","editorial-crispr-based-genome-editing-in-translational-research-2nd-edition","Editorial: CRISPR-Based Genome Editing in Translational Research - 2nd Edition","","The editorial introduces the second edition of the Cells Special Issue “CRISPR-Based Genome Editing in Translational Research,” co-edited by Jie Xu, Jifeng Zhang, and Dongshan Yang. It summarizes contributions spanning prime editing, balancing efficacy with safety concerns related to DNA repair pathways, and CRISPR-based disease modeling across species from zebrafish to non-human primates. It also highlights technical advances such as universal qPCR-based genotyping platforms and reviews on therapeutic strategies targeting cancer and other disease categories.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/editorial-crispr-based-genome-editing-in-translational-research-2nd-edition/465557/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/editorial-crispr-based-genome-editing-in-translational-research-2nd-edition/465557.png","ImageObject",300,407,{"name":92,"@type":93},"Damian","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the focus of this editorial and the special issue it introduces?","Question",{"text":112,"@type":113},"It provides an overview of contributions in the Special Issue on CRISPR-based genome editing in translational research, covering advances from fundamental biology to therapeutic applications.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does prime editing differ from conventional CRISPR nucleases in terms of DNA damage?",{"text":117,"@type":113},"Prime editors can introduce single-base substitutions, small insertions, and deletions without generating toxic DNA double-strand breaks, unlike conventional CRISPR nucleases.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is genotyping after CRISPR editing described as a challenge, and what solution is highlighted?",{"text":121,"@type":113},"CRISPR can produce multiple mutation types, complicating genotyping. The editorial highlights a reduced-cost, universal qPCR-based genotyping approach using a parallel qPCR iGenotype indexing strategy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},465557,1791160604,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":24,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},137451208677,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Editorial  \nEditorial: CRISPR-Based Genome Editing in Translational Research—2nd Edition  \nJie Xu *, Jifeng Zhang and Dongshan Yang  \nReceived: 3 December 2025  \nAccepted: 19 December 2025  \nPublished: 24 December 2025  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \nCenter for Advanced Models for Translational Sciences and Therapeutics, University of Michigan Medical School, 2800 Plymouth Road, Ann Arbor, MI 48109, USA  \n* [Correspondence: jiex@med.umich.edu](Correspondence: jiex@med.umich.edu)  \n1. Introduction  \nGenome editing technologies represented by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) have transformed biomedical research and therapeutic development [1–8] . The second edition of the Special Issue“CRISPR-Based Genome Editing in Translational Research” in Cells—co-edited by Drs. Jie Xu, Jifeng Zhang, and Dongshan Yang—highlights recent advances in the field, spanning fundamental biological insights to translational applications. We sincerely thank all the authors for their valuable contributions to this Special Issue. The following editorial provides an overview of these contributions and highlights emerging directions in this rapidly evolving field.  \n2. Advances and Applications in CRISPR Genome Editing  \n2.1. Prime Editing: Enhancing Efficacy and Addressing Safety—Where Is the Balance Point?  \nA featured review by Daliri et al. from the University of Cologne, Germany [9], presents the latest advances in prime editing, with particular emphasis on how this technology modulates cellular DNA repair pathways such as MLH1 (MutL Homolog 1)-mediated mismatch repair (MMR) to optimize efficacy and safety. Unlike conventional CRISPR nucleases, prime editors can introduce diverse single base pair substitutions, small insertions, and deletions without generating toxic DNA double-strand breaks (DSBs) [6–8,10] . However, as the authors cautioned, inhibition of the MMR pathway, which normally corrects mismatched nucleotides during DNA replication, may pose potential risks of tumorigenicity. This concern resonates with a recent report showing that inhibition of the non-homologous end joining (NHEJ) pathway, while increasing the frequency of homology-directed repair (HDR) events, also induced substantial genotoxic effects, including large-scale chromosomal rearrangements [11,12] .  \n2.2. Disease Modeling with CRISPR: From Zebrafish to Non-Human Primates  \nCRISPR/Cas9 revolutionized the development of animal models, especially in species where germline transmitting embryonic stem cells are not available, by enabling precise, efficient, and cost-effective genome editing, allowing scientists to replicate human disease mutations with unprecedented capacity [13–17] .  \nThis ability is exemplified by the work of Stemerdink et al. from Radboud University, Netherlands, in which they report the successful creation of a zebrafish line harboringa mutation in ADGRV1 in order to model retinal dysfunction in Usher syndrome [18] . This model accelerates both mechanistic research and preclinical therapy development for retinal disorders.  \nAt the other end of the phylogenetic spectrum, CRISPR was applied to engineer rhesus macaque embryos carrying expanded CAG repeats in the huntingtin gene, modeling the genetics of Huntington’s disease [19] . This non-human primate model would bridge the translational gap between rodent studies and human patients, offering an invaluable platform for elucidating disease pathophysiology and accelerating preclinical evaluation of genome editing strategies. Notably, in September 2025, UK researchers reported the first successful treatment of Huntington’s disease using a gene therapy delivered directly to the brain, which reduced disease progression by up to 75% in clinical trials (ClinicalTrials.gov ID ","cbCaitdoYCgxnCKv","https://ap.wps.com/l/cbCaitdoYCgxnCKv","pdf",214549,"English","# Introduction\n# Advances and Applications in CRISPR Genome Editing\n## Prime Editing: Enhancing Efficacy and Addressing Safety—Where Is the Balance Point?\n## Disease Modeling with CRISPR: From Zebrafish to Non-Human Primates\n## Streamlining Mutant Genotyping with Reduced Costs: A Universal qPCR-Based Platform for Genotyping Gene Editing Animals\n# Therapeutic Gene Editing: Emerging Models and Strategies\n## CRISPR-Assisted Evaluation of Drug Combinations for Treating Cancer","[{\"question\":\"What is the focus of this editorial and the special issue it introduces?\",\"answer\":\"It provides an overview of contributions in the Special Issue on CRISPR-based genome editing in translational research, covering advances from fundamental biology to therapeutic applications.\"},{\"question\":\"How does prime editing differ from conventional CRISPR nucleases in terms of DNA damage?\",\"answer\":\"Prime editors can introduce single-base substitutions, small insertions, and deletions without generating toxic DNA double-strand breaks, unlike conventional CRISPR nucleases.\"},{\"question\":\"Why is genotyping after CRISPR editing described as a challenge, and what solution is highlighted?\",\"answer\":\"CRISPR can produce multiple mutation types, complicating genotyping. The editorial highlights a reduced-cost, universal qPCR-based genotyping approach using a parallel qPCR iGenotype indexing strategy.\"}]","Editorial: CRISPR-Based Genome Editing in Translational Research - 2nd Edition | PDF",1790769765,13,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/c886e7f4818edc1062869628bf0173fc.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/b6dff96f8d6d05d44504e1d5dc5ab323.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/a3e041911903e5e8d006c43090da6d26.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/322c58d6951aa702396a1492c0fe0217.webp",980,1385]